atlasHold
2026-04-03 · earnings-review · Q4 FY25 confirms the FY2025 profitability inflection — first full-year GAAP profit in company history — but the underlying ORLADEYO growth trajectory is now structurally lower · Conviction 2/5
Open analysis → · PDF unavailable
Preview
# BCRX — Earnings Review Q4 FY25 (Atlas)
> Date: 2026-04-03
> Quarter: Q4 FY25 (Dec-2025)
> Market cap: $2.0B | EV/TTM Rev (ex-license): 3.4x | Revenue growth: +37.5% YoY (FY25 ORLADEYO)
## Verdict
Q4 FY25 confirms the FY2025 profitability inflection — first full-year GAAP profit in company history — but the underlying ORLADEYO growth trajectory is now structurally lower. US-only quarterly revenue of $151.7M declined 4.7% QoQ (European divestiture impact, not demand weakness), and FY2026 guidance of $625-645M implies only 12.8% normalized growth vs. the 37-43% pace of FY2025. The numbers were clean, management delivered on every FY2025 promise, and the navenibart Phase 3 enrollment is on track. But this is a transition year stock: the profitability story is proven, the growth story is fading, and the navenibart optionality won't resolve for 2+ years. Nothing in Q4 changes the thesis from my stock analysis two days ago. **Conviction: 2/5** — Watch. Not a growth portfolio candidate on forward metrics; interesting only if navenibart conviction is high.
## Qualification Gate
| Criterion | Threshold | BCRX Q4 FY25 | Status |
|-----------|-----------|--------------|--------|
| Revenue YoY growth | >30% | +37.5% FY25 ORLADEYO (trailing); **+12.8% FY26 guide (forward, normalized)** | PASS trailing / **FAIL forward** |
| Gross margin | >60% | 97.7% Q4 [GAAP] | PASS |
| Revenue per quarter | >$50M | $162.6M Q4 (ex-license) | PASS |
| Data availability | 4+ quarters | 16 quarters in DB | PASS |
| Share dilution | <10% annual | +5.7% FY25 (diluted: 207.4M to 219.3M) | PASS |
| GAAP profitability trajectory | Improving or positive | First full-year GAAP profit FY2025 ($263.9M NI) | PASS |
**Gate verdict: CONDITIONAL PASS.** Trailing FY2025 metrics pass. Forward FY2026 growth of 5-7% GAAP (12.8% normalized) fails the growth threshold. This company is transitioning from growth to mature franchise. Full analysis proceeds with that caveat.
## Six-Factor Score
| Factor | Rati
*…truncated*
Preview
# BCRX — Q4 FY25 Earnings Review
> **Date:** 2026-04-06
> **Quarter:** Q4 FY25 (Dec-2025) | **Reported:** Feb 26, 2026
> **Market cap:** $2.0B | **Run-rate P/S (ex-license):** 3.1x | **EV/FY26E Non-GAAP OI:** 11.4x
---
## Verdict
**BCRX does not belong in a concentrated growth portfolio.** Full stop. FY2025 was the capstone — first-ever full-year profitability, $601.8M ORLADEYO (+43% ex-Europe), $214M Non-GAAP OI. Excellent execution. But forward growth is 12.8% normalised. That's a mature franchise, not a compounder. Navenibart (approval ~late 2028) is a 2.5-year call option, not a near-term catalyst. At 3.1x P/S and 11.4x EV/Non-GAAP OI, the stock is fairly priced for what it is — but what it is doesn't fit my framework.
I haven't written about BCRX before, but applying my framework: **growth deceleration from 37-43% to 12.8% is a disqualifier.** You cannot dress this up. The EU divestiture explains it, but that doesn't change the forward math.
Atlas scored this at Conviction 2/5. I concur. The only path to re-rating is navenibart Phase 3 success — and that's 2028. I'm not paid to wait.
---
## The Numbers
### Revenue — 16 Quarters
| | Q1_22 | Q2_22 | Q3_22 | Q4_22 | Q1_23 | Q2_23 | Q3_23 | Q4_23 | Q1_24 | Q2_24 | Q3_24 | Q4_24 | Q1_25 | Q2_25 | Q3_25 | Q4_25 |
| | Mar-22 | Jun-22 | Sep-22 | Dec-22 | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev ($m) | 49.9 | 65.5 | 75.8 | 79.5 | 68.8 | 82.5 | 86.7 | 93.4 | 92.8 | 109.3 | 117.1 | 131.5 | 145.5 | 163.4 | 159.4 | 406.6* |
| YoY % | — | — | — | — | +38% | +26% | +14% | +18% | +35% | +33% | +35% | +41% | +57% | +50% | +36% | +209%* |
| QoQ % | — | +31% | +16% | +5% | -14% | +20% | +5% | +8% | -1% | +18% | +7% | +12% | +11% | +12% | -2% | +155%* |
\* Q4_FY25 total inflated by **$244M one-time European ORLADEYO license fee.** Underlying quarterly revenue: **$162.6M (+23.7% Y
*…truncated*
Rolling earnings (raw)
# BCRX — Rolling Earnings Summary
> Last updated: 2026-04-03
> Window: Q1 FY25 — Q4 FY25
---
## Financial Grid (4 Quarters)
| | Q1_FY25 | Q2_FY25 | Q3_FY25 | Q4_FY25 |
| | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 |
|---|---|---|---|---|
| Revenue ($m) | 145.5 | 163.4 | 159.4 | 406.6* |
| ORLADEYO ($m) | 134.2 | 156.8 | 159.1 | 151.7 |
| License Rev ($m) | — | — | — | 244.0 |
| YoY % (total) | +56.8% | +49.5% | +36.1% | +209.2%* |
| QoQ % (total) | +10.6% | +12.3% | -2.4% | +155.1%* |
| GM % [GAAP] | 96.8% | 98.3% | 98.6% | 97.7% |
| OpM % [GAAP] | +14.6% | +18.2% | +18.6% | +64.0%* |
| OpM % [Non-GAAP] | 29.3% | 34.9% | 32.4% | 38.4%** |
| Non-GAAP OI ($m) | 42.6 | 57.0 | 51.7 | 62.4 |
| NI ($m) [GAAP] | 0.0 | 5.1 | 12.9 | 245.8* |
| EPS [GAAP] | $0.00 | $0.02 | $0.06 | $1.12* |
| SBC ($m) | 21.4 | 21.3 | 18.6 | 23.8 |
| Shares (diluted, M) | 215.3 | 219.9 | 219.9 | 219.3 |
| Verdict | Breakeven inflection | Record NRx, strong margins | Flat QoQ (EU exit noise) | FY25 capstone: profitability proven |
\* Q4_FY25 inflated by $244M one-time European ORLADEYO license revenue.
\** Q4_FY25 non-GAAP op margin on ex-license revenue base ($162.6M).
**Full Year FY2025:**
- ORLADEYO: $601.8M (+37.5% GAAP; +43.0% ex-Europe)
- Non-GAAP OI: $214.2M (+240% YoY)
- GAAP NI: $263.9M (first full-year profitability in company history)
- GAAP EPS: $1.21
- SBC: $85.1M (+30% YoY)
---
## Trajectory
ORLADEYO revenue accelerated for three consecutive years (FY23 +30%, FY24 +34%, FY25 +38%), but FY2026 guidance of $625-645M implies +12.8% normalized growth (US-only basis). The deceleration is structural (European divestiture + US market maturation), not operational. Navenibart (Phase 3, approval ~late 2028) is the next growth vector.
---
## Promise Tracker
| Quarter | Promise | Outcome | Status |
|---------|---------|---------|--------|
| Q4 FY24 | FY2025 ORLADEYO $535-550M | $601.8M actual | **Beat — +$51.8M vs high end** |
| Q1 FY25 | Raised FY2025 to $580-600M | $601.8M actual | **Beat — +$1.8M vs high end** |
| Q2 FY25 | Maintained $580-600M | $601.8M actual | **Met — conservative hold confirmed** |
| Q3 FY25 | Raised to $590-600M | $601.8M actual | **Beat — +$1.8M vs high end** |
| Q4 FY25 | FY2026 ORLADEYO $625-645M | — | Pending |
| Q4 FY25 | FY2026 Total Rev $635-660M | — | Pending |
| Q4 FY25 | FY2026 Non-GAAP OpEx $450-470M | — | Pending |
| Q4 FY25 | Alpha Orbit enrollment mid-2026 | — | Pending ("very well") |
| Q4 FY25 | Navenibart BLA end-2027 | — | Pending |
| Q4 FY25 | BCX17725 Phase 1 data year-end 2026 | — | Pending |
| Q4 FY25 | No equity raise planned | — | Pending (watch share count) |
**Pattern:** Management sandbagged FY2025 initial guidance by 10.9%. All four guidance updates were beat. Guidance credibility is high. FY2026 initial guide may prove similarly conservative, but growth ceiling is lower (US-only market).
---
## Language Shift Monitor
| Topic | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|-------|---------|---------|---------|---------|
| Growth narrative | Unknown | Unknown | Unknown | "Fundamentally transformative" — celebratory |
| Competition | Unknown | Unknown | Unknown | "Structurally segmented market" — deflecting specifics |
| Navenibart positioning | Unknown | Unknown | Unknown | "Complement rather than replace" — pre-empting cannibalization Qs |
| Profitability | Unknown | Unknown | Unknown | "Highest ever" / "first time in company history" |
| Forward caution | Unknown | Unknown | Unknown | Pre-emptively flagged Q1 soft / back-half loading |
**Note:** Q1-Q3 FY25 transcripts not available (paywalled). Language tracking begins from Q4 FY25.
---
## Analyst Concern Tracker
| Concern | First Raised | Status |
|---------|-------------|--------|
| Competitive erosion from 3 new HAE approvals (mid-2025) | Q3 FY25 | Active — no visible erosion yet; "slightly beat" prior-year NRx despite launches |
| ORLADEYO growth deceleration | Q4 FY25 | Active — FY26 guide confirms structural slowdown to 12.8% normalized |
| Navenibart cannibalization of ORLADEYO | Q4 FY25 | Pre-empted by management — "complement" framing |
| Balance sheet leverage (Blackstone + royalty) | Q4 FY25 | Active — ~$860M+ claims on $2B market cap |
| Patent cliff / ORLADEYO exclusivity | Not raised on call | Absent from discussion — notable gap (patents to 2039, but not discussed) |
| Patient count disclosure stopped | Q4 FY25 (wsm) | Active — last absolute count was 1,104 in Q4 FY23. Two years without disclosure. Only qualitative "record NRx" claims since. |
---
## Source Log
| Date | Persona | What Changed |
|------|---------|-------------|
| 2026-04-03 | atlas | Created _ROLLING.md from Q4 FY25 earnings review. Populated financial grid, promise tracker, language shift monitor, analyst concerns. |
| 2026-04-06 | wsm | Reviewed Q4 FY25 earnings. Concur with atlas assessment. Added analyst concern: patient count disclosure stopped since Q4 FY23. Flagged double-warning: growth decelerating + margins compressing FY26. Not a growth candidate (12.8% forward). |